Bristol Myers Squibb

News

Opdivo backed by NICE for rare gastro-oesophageal cancers

Bristol-Myers Squibb's Opdivo has been recommended as a treatment for around 3,000 people with rare forms of gastro-oesophageal cancer via the NHS in England and Wales.

News

BMS announces positive Reblozyl phase 3 results for MDS

Bristol Myers Squibb has announced positive topline results from its

News

West Chester - Circa November 2020: AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

AstraZeneca gets first okay for CTLA4 drug tremelimumab

AstraZeneca's lengthy and turbulent development of CTLA4 inhibitor tremelimumab has at least led to a regulatory approval as part of a combination therapy for advanced liver cancer.

News

BMS lines up follow-up indication for cardiomyopathy drug Ca...

Bristol-Myers Squibb is going after a second indication for its first-to-market cardiac myosin inhibitor Camzyos, a drug tipped to be a future blockbuster and the top prospect in the compan

News

Immutep's LAG-3 drug 'dramatically undervalued,' says analys...

Australian biotech Immutep's LAG-3 checkpoint inhibitor eftilagimod alpha (efti) may not be the first drug in the class to reach the market, but is a strong contender and, according to at l

News